DE69837211T2 - Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis - Google Patents

Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis Download PDF

Info

Publication number
DE69837211T2
DE69837211T2 DE69837211T DE69837211T DE69837211T2 DE 69837211 T2 DE69837211 T2 DE 69837211T2 DE 69837211 T DE69837211 T DE 69837211T DE 69837211 T DE69837211 T DE 69837211T DE 69837211 T2 DE69837211 T2 DE 69837211T2
Authority
DE
Germany
Prior art keywords
virus
vaccine
vero cells
attenuated
vero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837211T
Other languages
German (de)
English (en)
Other versions
DE69837211D1 (de
Inventor
Hyun Su Kim
Wang Don Yoo
Soo Ok Kim
Sung Hee Lee
Sang Bum Moon
Sun Pyo Hong
Yong Cheol Shin
Yong Ju Chung
Kenneth H. Washington ECKELS
Bruce Washington INNIS
Joseph R. Washington PUTNAK
Leonard N. Washington BINN
Ashok K. Washington SRIVASTAVA
Doria R. Washington DUBOIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
Walter Reed Army Institute of Research
United States Department of the Army
Original Assignee
CJ Corp
Walter Reed Army Institute of Research
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, Walter Reed Army Institute of Research, United States Department of the Army filed Critical CJ Corp
Priority to DE122009000037C priority Critical patent/DE122009000037I2/de
Application granted granted Critical
Publication of DE69837211D1 publication Critical patent/DE69837211D1/de
Publication of DE69837211T2 publication Critical patent/DE69837211T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69837211T 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis Expired - Lifetime DE69837211T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122009000037C DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR4200297 1997-08-28
KR19970042002 1997-08-28
KR4200197 1997-08-28
KR19970042001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
DE69837211D1 DE69837211D1 (de) 2007-04-12
DE69837211T2 true DE69837211T2 (de) 2007-12-06

Family

ID=26633032

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69837211T Expired - Lifetime DE69837211T2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis
DE122009000037C Active DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122009000037C Active DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Country Status (15)

Country Link
US (1) US6309650B1 (https=)
EP (2) EP1025209B1 (https=)
JP (1) JP4161017B2 (https=)
KR (1) KR100314404B1 (https=)
CN (1) CN1142271C (https=)
AU (1) AU748730B2 (https=)
CA (1) CA2301000C (https=)
DE (2) DE69837211T2 (https=)
DK (2) DK1025209T3 (https=)
ES (2) ES2382946T3 (https=)
FR (1) FR09C0037I2 (https=)
MY (1) MY129773A (https=)
NL (1) NL300391I2 (https=)
NZ (1) NZ503522A (https=)
WO (1) WO1999011762A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
US6841374B1 (en) 1998-10-05 2005-01-11 Research Foundation For Microbial Diseases Of Osaka University Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
DK2251419T3 (da) * 1999-04-22 2012-07-02 Us Agriculture Porcint reproduktions- og respirations-syndrom-vaccine baseret på isolat JA-142
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
KR20160003301A (ko) * 2007-12-26 2016-01-08 기타사토 다이이치 산쿄 백신 가부시키가이샤 안정하게 장기간 보존할 수 있는 일본뇌염 백신의 제조방법 및 그 백신의 용도
EP2298344B1 (en) * 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
ES2647882T3 (es) 2011-12-06 2017-12-27 Valneva Austria Gmbh Compuestos de aluminio para su uso en productos terapéuticos y vacunas
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
RU2706693C2 (ru) * 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Вирусная вакцина и способы ее производства
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
EP3403671B1 (en) * 2016-01-15 2023-06-07 KM Biologics Co., Ltd. Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CN116983398A (zh) 2017-11-30 2023-11-03 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物以及其使用方法
CN110684747B (zh) 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
WO2020045368A1 (ja) * 2018-08-27 2020-03-05 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬，ワクチンなどの評価方法
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP4114456A1 (en) 2020-03-06 2023-01-11 The Colorado State University Research Foundation Production of vaccines comprising inactivated sars-cov-2 viral particles
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A4 (en) * 2022-04-20 2025-11-19 Korea Nat Institute Of Health GENOTYPE 5 OF HIGH-TIRES JAPANESE ENCEPHALITIS VIRUS AND ITS USE
EP4652265A1 (en) 2023-01-18 2025-11-26 Valneva Austria GmbH Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
AU748730B2 (en) 2002-06-13
DE122009000037I1 (de) 2009-11-05
US6309650B1 (en) 2001-10-30
KR100314404B1 (ko) 2002-10-12
EP1604685A2 (en) 2005-12-14
EP1025209A1 (en) 2000-08-09
FR09C0037I2 (fr) 2021-11-05
MY129773A (en) 2007-04-30
EP1604685A3 (en) 2006-07-05
JP4161017B2 (ja) 2008-10-08
NL300391I2 (nl) 2009-11-02
EP1604685B1 (en) 2012-02-22
FR09C0037I1 (https=) 2009-09-25
CA2301000C (en) 2003-07-08
CN1272879A (zh) 2000-11-08
DK1604685T3 (da) 2012-06-18
CN1142271C (zh) 2004-03-17
ES2281929T3 (es) 2007-10-01
AU9004798A (en) 1999-03-22
JP2001514844A (ja) 2001-09-18
DE69837211D1 (de) 2007-04-12
WO1999011762A1 (en) 1999-03-11
EP1025209B1 (en) 2007-02-28
DK1025209T3 (da) 2007-06-25
DE122009000037I2 (de) 2011-06-16
KR19990023955A (ko) 1999-03-25
CA2301000A1 (en) 1999-03-11
NZ503522A (en) 2001-06-29
NL300391I1 (nl) 2009-08-03
ES2382946T3 (es) 2012-06-14

Similar Documents

Publication Publication Date Title
DE69837211T2 (de) Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis
JP5554646B2 (ja) フラビウイルスワクチン
KR20220144415A (ko) 백신 조성물
AT410634B (de) Attenuierte lebendimpfstoffe
AU2012360168A1 (en) Vaccines directed against human Enteroviruses
DE69934583T2 (de) Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
CN107050445A (zh) 灭活登革热病毒疫苗
JP6985384B2 (ja) 弱毒変異型ジカウイルスを含むワクチン組成物
CN101352569B (zh) 二倍体细胞乙型脑炎疫苗及纯化乙型脑炎疫苗的制备方法
US20080107685A1 (en) Live Attenuated Dengue 3 Virus Strains
JP2019522986A (ja) 弱毒化突然変異体ジカウイルスをコードするゲノム配列
KR20010032699A (ko) 일본 뇌염 바이러스 감염에 대한 불활성 백신을 위한증강된 면역원 및 그 제조방법
CN113186171B (zh) 一种黄病毒属病毒的减毒病毒及其用途
WO2010137036A2 (en) Novel japanese encephalitis vaccine and method of manufacturing the same
DE69433760T2 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
KR900007262B1 (ko) 신(腎)증후성 출혈열 비루스 항원의 제조방법, 및 그 항원을 함유하는 백신 및 신증후성 출혈열 진단제
DE69224590T2 (de) Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine
JP2007068401A (ja) 西ナイルウイルスワクチン
DE69927769T2 (de) Verfahren zur herstellung von viren aus zellkulturen
TWI228147B (en) An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
JP2002514088A (ja) ウイルス減毒法
CN1871026A (zh) 黄病毒疫苗
HK1099207A (en) Flavivirus vaccines
HK1194432A (en) Flavivirus vaccines
HK1194432B (en) Flavivirus vaccines